ImmuneRegen BioSciences’ drug candidate Homspera Confirms efficacy

December 14, 2009

By Flinn Foundation

[Source: CNN Money] – ImmuneRegen BioSciences Inc.®, a wholly owned subsidiary of IR Biosciences Holdings Inc. (OTCBB: IRBS), today announced that treatment with its lead compound, Homspera, revealed that Homspera improved the efficacy of a novel cancer vaccine which significantly reduced tumor growth and greatly improved long-term survival in an animal model of skin cancer. These are the latest findings supporting the vaccine adjuvant capability of Homspera, and extend to the cancer vaccine space in addition to previously shown efficacy of Homspera in infectious disease models such as influenza.

For more information: ImmuneRegen BioSciences'(R) Drug Candidate Homspera Confirms Efficacy as Cancer Vaccine Adjuvant